SiBone

SIBN Healthcare Medical Devices

SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024.

Revenue
+14.5%
EPS
+26.7%
Free cash flow
+31.1%
Total debt
+0.33%

Quarter to September 2026, against a year earlier

24.20 0.07 −0.29%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−52.9×
Dividend yield
—
F-score
6/9
Altman Z
7.18
Beneish M
−3.08
Dividend safety
n/a

SiBone (SIBN) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, SiBone (SIBN) trades at a EV/Sales of 4.4×. Over the past ten years it has ranged from 1.1× (January 2019) to 13.5× (May 2021); the current reading is higher than 47% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.7× 30.85%
FY2024 2.8× (42.14%)
FY2023 4.8× 30.44%
FY2022 3.7× (46.51%)
FY2021 6.9× (29.34%)
FY2020 9.8× 38.07%
FY2019 7.1× 332.59%
FY2018 1.6× (21.41%)
FY2017 2.1× 0.00%
FY2016 2.1× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.3× 15.31%
Jun 2026 2.9× 33.09%
Mar 2026 2.2× (40.78%)
Dec 2025 3.7× 34.62%
32 more quarters

Against its own ten years

Low 1.1× High 13.5×
Ten-year median 4.8×
Current reading's percentile 47

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on SIBN